We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


DiaSorin Molecular LLC manufactures and distributes innovative molecular diagnostic products on the versatile LIAISON... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Automated Assays Evaluated For High-Sensitivity Thyroglobulin Measurement

By LabMedica International staff writers
Posted on 12 Aug 2021
Print article
The LIAISON XL is a fully automated chemiluminescence analyzer, performing complete sample processing as well as measurement and evaluation (Photo courtesy of DiaSorin)
The LIAISON XL is a fully automated chemiluminescence analyzer, performing complete sample processing as well as measurement and evaluation (Photo courtesy of DiaSorin)
Thyroglobulin (Tg) is a tumor marker for differentiated thyroid carcinoma (DTC) originating from thyroid follicular cell and is an important tumor marker for therapy control. Over the past decade, assays for highly sensitive Tg measurement have become increasingly established.

Differentiated thyroid carcinoma, namely papillary and follicular thyroid carcinoma, makes up about 94% of these cases. Despite the generally good prognosis of thyroid carcinoma, about 5% of patients will develop metastatic disease which fails to respond to radioactive iodine, exhibiting a more aggressive behavior.

Clinical Laboratorians at the University Hospital of Essen (Essen, Germany) and their associate determined Tg values of 166 sera from subjects without thyroid diseases and of more than 500 sera of well-defined DTC patients. Histologically diagnosed papillary, follicular, oncocytic (Hürthle cell), or poorly differentiated thyroid carcinomas are referred to as thyroid follicular cell-derived differentiated thyroid carcinomas (DTC). The study groups were divided in separate cohorts and sub-groups.

To measure the Tg the investigators compared three different assays. The Medizym Tg Rem assay (Medipan, Blankenfelde-Mahlow, Germany), which is a manual two-step sandwich immunoenzymometric assay (IEMA) with two monoclonal antibodies directed against different epitopes of the Tg molecule. For the measurement of Tg values that are above the functional measuring range of the Tg Rem assay, they used in the Medipan SELco Tg assay, a manual immunoradiometric assay (IRMA) with two monoclonal antibodies.

The team also compared the Elecsys Tg II (Roche, Basel, Switzerland) which is an electrochemiluminescence immunoassay (ECLIA) for the Cobas automated system which uses biotinylated monoclonal Tg-specific antibodies and monoclonal Tg-specific antibodies labeled with a ruthenium complex that form a sandwich complex with Tg molecules in the sample. The other assay was the LIAISON Tg II Gen assay was run on a LIAISON XL analyzer (DiaSorin, Saluggia, Italy). The LIAISON XL analyzer is a fully automated chemiluminescence analyzer that adopts a “flash” chemiluminescence technology (CLIA) with paramagnetic microparticle solid phase. TgAb determinations were performed on the Immulite 2000XPi Immunoassay system (Siemens Healthineers, Eschborn, Germany).

The scientists reported that Tg reference values from healthy subjects were up to 37.93 ng/mL (women) and 24.59 ng/mL (men) with the LIAISON Tg II Gen assay. Tg values showed good correlations in healthy subjects and patients with active tumorous disease. In contrast, Tg values in the very low range from cured thyroidectomized patients were poorly comparable between the three assays, while clinical differences between the cohorts were correctly reflected by all assays.

The authors concluded that the data from their study demonstrated that with the new LIAISON Tg II Gen assay another assay running on an automated laboratory platform for measurement of Tg values ranging from the highly sensitive up to a pronounced increased level is available. In TgAb sera of DTC patients depicted different results between assays indicating different interferences of TgAb's with assay antibodies. The study was published on July 27, 2021 in the journal Practical Laboratory Medicine.

Related Links:

University Hospital of Essen 
Siemens Healthineers

Gold Supplier
Microplate Washer
Single Channel Pipette
AHN pipet4u pro
Silver Supplier
Cartridge Incubator
WS-i60 Cartridge Incubator
Gold Supplier
Fluorimetric Immunoassay Analyzer
Confiscope F20

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.